Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.
Curr Breast Cancer Rep., Dec;3(4):205-211 (2011)
Quantitative assessment of dynamic PET imaging data in cancer imaging.
Magn Reson Imaging., Nov;30(9):1203-15 (2012)
Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials.
Magn Reson Imaging., Nov;30(9):1291-300 (2012)
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.
EJNMMI Res., 2(1):34 (2012)
Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.
Nucl. Med. Biol., Oct;38(7):969-78 (2011)
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
J. Nucl. Med., Oct;52(10):1541-9 (2011)
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Clin. Cancer Res., Jul;17(14):4799-805 (2011)
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Clin. Cancer Res., Apr;17(8):2400-9 (2011)
Breast cancer and hormonal stimulation: is glycolysis the first sign of response?
J. Nucl. Med., Nov;51(11):1663-4 (2010)
Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
Clin. Cancer Res., May;16(10):2803-10 (2010)
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
J. Clin. Oncol., Sep;26(27):4449-57 (2008)
Tumor receptor imaging.
J. Nucl. Med., Jun;49 Suppl 2:149S-63S (2008)
Challenges in clinical studies with multiple imaging probes.
Nucl. Med. Biol., Oct;34(7):879-85 (2007)
Semin Nucl Med., Nov;37(6):470-6 (2007)
Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group study.
Cancer Nurs., 30(4):261-9 (2007 Jul-Aug)
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
J. Clin. Oncol., Feb;25(6):656-61 (2007)
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Breast Cancer Res. Treat., Sep;105(1):87-94 (2007)
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Clin. Cancer Res., Oct;12(19):5608-10 (2006)
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
J. Clin. Oncol., Jun;24(18):2793-9 (2006)
The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma.
Cancer., Nov;104(10):2054-62 (2005)